Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”
暂无分享,去创建一个
M. Weichenthal | A. Hauschild | D. Schadendorf | H. Schlemmer | S. Reske | W. Wick | A. Blum | A. Mackensen | C. Garbe | M. Ganten | P. Hohenberger | R. Gutzmer | C. Sander | D. Vordermark | R. Kortmann | C. Loquai | U. Kleeberg | R. Voltz | D. Nashan | M. Kaatz | J. Hassel | O. Kölbl | M. Follmann | B. Frerich | A. Krause-Bergmann | C. Löser | U. Leiter | C. Rose | P. Kurschat | U. Trefzer | P. Mohr | C. Sunderkötter | F. Meier | T. Eigentler | E. Dippel | M. Schiller | A. Pflugfelder | I. Satzger | H. Link | P. Feyer | C. Kochs | S. Wesselmann | Marcus Capellaro | J. Hübner | T. Dettenborn | J. Gärtner | L. Swoboda | A. Weyergraf | M. Möhrle | G. Strittmatter | D. Dill | C. Czeschik | A. Werner | A. Krause‐Bergmann
[1] F. Roila,et al. [Cancer-related fatigue]. , 2015, Recenti progressi in medicina.
[2] J. Armitage,et al. Myeloid growth factors. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.
[3] F. Nocera. Communication in oncology , 2013 .
[4] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[5] R. Fisher,et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. , 2012, The Lancet. Oncology.
[6] M. Hočevar,et al. Adjuvant radiotherapy for palpable melanoma metastases to the groin: when to irradiate? , 2012, International journal of radiation oncology, biology, physics.
[7] D. Cella,et al. Health-related quality of life among patients with metastatic melanoma: results from an international phase 2 multicenter study , 2012, Melanoma research.
[8] Sandra Nolte,et al. Systematic skin cancer screening in Northern Germany. , 2012, Journal of the American Academy of Dermatology.
[9] D. Schadendorf,et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. , 2012, European journal of cancer.
[10] H. Gollnick,et al. Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry. , 2012, Journal of the American Academy of Dermatology.
[11] Andrew Hayen,et al. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Weichenthal,et al. Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient’s choice: a multicentre Dermatologic Cooperative Oncology Group trial , 2011, Melanoma research.
[13] S. O’Day,et al. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial , 2011, Melanoma research.
[14] K. Drzewiecki,et al. Extensive screening for primary tumor is redundant in melanoma of unknown primary , 2011, Journal of surgical oncology.
[15] A. V. van Geel,et al. Long‐term outcome of isolated limb perfusion with tumour necrosis factor‐α for patients with melanoma in‐transit metastases , 2011, The British journal of surgery.
[16] M. Beutel,et al. Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-α2b: patients' and doctors' views. , 2011, European journal of dermatology : EJD.
[17] H. Cabo,et al. Dermoscopy of pigmented lesions of the mucosa and the mucocutaneous junction: results of a multicenter study by the International Dermoscopy Society (IDS). , 2011, Archives of dermatology.
[18] R. Gutzmer,et al. Age as a key factor influencing metastasizing patterns and disease‐specific survival after sentinel lymph node biopsy for cutaneous melanoma , 2011, International journal of cancer.
[19] U. Kleeberg,et al. Individuelle Behandlung für Patienten mit fortgeschrittenem Krebs , 2011 .
[20] C. Robert,et al. New drugs in melanoma: it's a whole new world. , 2011, European journal of cancer.
[21] C. Garbe,et al. Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: Review of the literature and recommendations for general practice , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[22] K. Nouri,et al. Surgical Treatments for Lentigo Maligna: A Review , 2011, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
[23] R. Sullivan,et al. Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma , 2011, Melanoma research.
[24] K. Flaherty,et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] D. Schadendorf,et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). , 2011, European journal of cancer.
[26] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[27] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[28] C. Antonescu,et al. KIT as a therapeutic target in metastatic melanoma. , 2011, JAMA.
[29] F. Marincola,et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. , 2011, The New England journal of medicine.
[30] I. V. D. van der Ploeg,et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] A. Enk,et al. Algorithm for detection of small-bowel metastasis in malignant melanoma of the skin. , 2011, Endoscopy.
[32] A. Eggermont,et al. Outcome After Therapeutic Lymph Node Dissection in Patients with Unknown Primary Melanoma Site , 2011, Annals of Surgical Oncology.
[33] J. Kirkwood,et al. Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697) . , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] H. Wolf,et al. Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] A. Hauschild,et al. Health-related Quality of Life Before and During Adjuvant Interferon-&agr; Treatment for Patients With Malignant Melanoma (DeCOG-Trial) , 2011, Journal of immunotherapy.
[36] M. Mihm,et al. AJCC melanoma staging update: impact on dermatopathology practice and patient management , 2011, Journal of cutaneous pathology.
[37] G. Lyman,et al. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] C. Slingluff,et al. Intraoperative Imaging Guidance for Sentinel Node Biopsy in Melanoma Using a Mobile Gamma Camera , 2011, Annals of surgery.
[39] M. Ernstoff,et al. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] J. Gaertner,et al. Standardizing integration of palliative care into comprehensive cancer therapy—a disease specific approach , 2011, Supportive Care in Cancer.
[41] J. V. Von Roenn,et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] I. Bilbao,et al. Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma , 2011, Journal of hepato-biliary-pancreatic sciences.
[43] J. Utikal,et al. Comparison of the diagnostic accuracy of whole‐body MRI and whole‐body CT in stage III/IV malignant melanoma , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[44] Isaak Hatami,et al. Palliative cancer care: an epidemiologic study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] Thomas J. Smith,et al. American society of clinical oncology statement: toward individualized care for patients with advanced cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] J. Bibault,et al. Adjuvant radiation therapy in metastatic lymph nodes from melanoma , 2011, Radiation oncology.
[47] B. Pockaj,et al. Desmoplastic melanoma – the step‐child in the melanoma family? , 2011, Journal of surgical oncology.
[48] Yan Xing,et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. , 2011, Journal of the National Cancer Institute.
[49] H. Minn,et al. Melanoma Imaging with Highly Specific PET Probes: Ready for Prime Time? , 2011, The Journal of Nuclear Medicine.
[50] A. Hauschild,et al. Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects , 2011, The oncologist.
[51] J. Ahrar,et al. Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma , 2011, Cancer investigation.
[52] J. Zwingmann,et al. Arzt-Patienten-Kommunikation in der Onkologie , 2011, Nervenheilkunde.
[53] J. Cormier,et al. Assessment of patient-reported outcomes in patients with melanoma. , 2011, Surgical oncology clinics of North America.
[54] D. Tyler,et al. Regional treatment strategies for in-transit melanoma metastasis. , 2011, Surgical oncology clinics of North America.
[55] N. Kearney,et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. , 2011, European journal of cancer.
[56] C. Garbe,et al. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up , 2011, Cancer Immunology, Immunotherapy.
[57] O. Gefeller,et al. Malignant Melanoma of the Skin: Long-term Follow-up and Time to First Recurrence , 2011, World Journal of Surgery.
[58] A. Hauschild,et al. Sentinel Node Dissection Delays Recurrence and Prolongs Melanoma-Related Survival: An Analysis of 673 Patients from a Single Center with Long-Term Follow-Up , 2011, Annals of Surgical Oncology.
[59] S. Hochwald,et al. Epitrochlear Lymph Node Dissection , 2011, Annals of Surgical Oncology.
[60] B. Pockaj,et al. Risk factors associated with local and in-transit recurrence of cutaneous melanoma. , 2010, American Journal of Surgery.
[61] E. Erdei,et al. A new understanding in the epidemiology of melanoma , 2010, Expert review of anticancer therapy.
[62] M. Somerfield,et al. American society of clinical oncology/american society of hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. , 2010, Journal of oncology practice.
[63] J. Hafner,et al. Microscopically controlled surgery (MCS) , 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[64] G. Morgan,et al. Antitumor effects and anticancer applications of bisphosphonates. , 2010, Seminars in oncology.
[65] T. Nijsten,et al. Melanoma survivors are dissatisfied with perceived information about their diagnosis, treatment and follow‐up care , 2010, The British journal of dermatology.
[66] A. Stromberg,et al. Surveillance after surgical treatment of melanoma: futility of routine chest radiography. , 2010, Surgery.
[67] W. Chie,et al. An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patients. , 2010, European journal of cancer.
[68] C. Revel,et al. La TEP-TDM au 18FDG a-t-elle un intérêt dans la stadification ganglionnaire des mélanomes malins cutanés cervicofaciaux bénéficiant de la technique du ganglion sentinelle ? À propos de 22 cas , 2010 .
[69] C. Garbe,et al. High response rate after intratumoral treatment with interleukin‐2 , 2010, Cancer.
[70] M. Fujiwara,et al. Mid-arm lymph nodes dissection for melanoma. , 2010, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.
[71] E. Bruera,et al. Integrating supportive and palliative care in the trajectory of cancer: establishing goals and models of care. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] Alona Muzikansky,et al. Early palliative care for patients with metastatic non-small-cell lung cancer. , 2010, The New England journal of medicine.
[73] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[74] T. Chua,et al. Surgical metastasectomy in AJCC stage IV M1c melanoma patients with gastrointestinal and liver metastases. , 2010, Annals of the Academy of Medicine, Singapore.
[75] Sergi Vidal-Sicart,et al. Added Value of Intraoperative Real-Time Imaging in Searches for Difficult-to-Locate Sentinel Nodes , 2010, The Journal of Nuclear Medicine.
[76] M. Hočevar,et al. Melanoma metastases to the neck nodes: role of adjuvant irradiation. , 2010, International journal of radiation oncology, biology, physics.
[77] R. Elashoff,et al. The Impact on Morbidity and Length of Stay of Early Versus Delayed Complete Lymphadenectomy in Melanoma: Results of the Multicenter Selective Lymphadenectomy Trial (I) , 2010, Annals of Surgical Oncology.
[78] R. Gutzmer,et al. Comparison of classification systems in melanoma sentinel lymph nodes—An analysis of 697 patients from a single center , 2010, Cancer.
[79] S. Florell,et al. Comparative Analysis of Total Body and Dermatoscopic Photographic Monitoring of Nevi in Similar Patient Populations at Risk for Cutaneous Melanoma , 2010, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
[80] A. L. Bowen,et al. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma. , 2010, Archives of surgery.
[81] P. Nathan,et al. Revised U.K. guidelines for the management of cutaneous melanoma 2010 , 2010, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.
[82] D. Coit,et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] P. Huppert,et al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. , 2010, European Journal of Radiology.
[84] T. Borght,et al. The diagnostic accuracy of 18F-FDG PET in cutaneous malignant melanoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[85] M. Nicolson,et al. Patient satisfaction with GP-led melanoma follow-up: a randomised controlled trial , 2010, British Journal of Cancer.
[86] Jeffrey E Gershenwald,et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] C. Garbe,et al. Incisional biopsy and melanoma prognosis: Facts and controversies. , 2010, Clinics in dermatology.
[88] C. Garbe,et al. Determinants of survival in patients with brain metastases from cutaneous melanoma , 2010, British Journal of Cancer.
[89] L. de la Cruz-Merino,et al. Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. , 2010, The oncologist.
[90] J. Klode,et al. Sentinel Lymph Node Excision and PET‐CT in the Initial Stage of Malignant Melanoma: A Retrospective Analysis of 61 Patients with Malignant Melanoma in American Joint Committee on Cancer Stages I and II , 2010, Dermatologic Surgery.
[91] H. Neuss,et al. Postoperative surgical complications after radical axillary lymph node dissection in melanoma disease result in increased pain. , 2010, International surgery.
[92] Nassir Navab,et al. First demonstration of 3-D lymphatic mapping in breast cancer using freehand SPECT , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[93] A. Stromberg,et al. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy? , 2010, Cancer.
[94] E. Thiel,et al. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome , 2010, Melanoma research.
[95] Rory Wolfe,et al. The impact of partial biopsy on histopathologic diagnosis of cutaneous melanoma: experience of an Australian tertiary referral service. , 2010, Archives of dermatology.
[96] W. Al-Refaie,et al. Conditional Survival After Surgical Treatment of Melanoma: An Analysis of the Surveillance, Epidemiology, and End Results Database , 2010, Annals of Surgical Oncology.
[97] W. Vogel,et al. Utility of FDG PET/CT and Brain MRI in Melanoma Patients with Increased Serum S-100B Level During Follow-up , 2010, Annals of Surgical Oncology.
[98] A. Eggermont,et al. Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[99] D. Razavi,et al. Cancer patients' desire for psychological support: prevalence and implications for screening patients' psychological needs , 2010, Psycho-oncology.
[100] P. Butow,et al. Shared decision making coding systems: how do they compare in the oncology context? , 2010, Patient education and counseling.
[101] P. Payoux,et al. Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients , 2009, The British journal of dermatology.
[102] S. Mocellin,et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. , 2010, Journal of the National Cancer Institute.
[103] A. Pavlick,et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma , 2011, Investigational New Drugs.
[104] P. Hersey,et al. A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy , 2010, Molecular Cancer.
[105] S. Gambhir,et al. Meta-analysis of the performance of 18F-FDG PET in cutaneous melanoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[106] Jeffrey E Gershenwald,et al. Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[107] M. Ballo,et al. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high‐risk, lymph node‐metastatic melanoma , 2009, Cancer.
[108] K. Flaherty,et al. Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases , 2009, Clinical Cancer Research.
[109] S. Menzies,et al. Impact of dermoscopy and short‐term sequential digital dermoscopy imaging for the management of pigmented lesions in primary care: a sequential intervention trial , 2009, The British journal of dermatology.
[110] R. Hornik,et al. Patient-clinician information engagement increases treatment decision satisfaction among cancer patients through feeling of being informed. , 2009, Patient education and counseling.
[111] P. Butow,et al. Evidence-based Dermatology: Study Psychological Responses and Coping Strategies among Patients with Malignant Melanoma a Systematic Review of the Literature for Editorial Comment See Page 1439 , 2022 .
[112] V. Servois,et al. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[113] M. Mihm,et al. Expert opinion in melanoma: the sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden. , 2009, European journal of cancer.
[114] K. Shannon,et al. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma , 2009, The Australasian journal of dermatology.
[115] R. Scolyer,et al. Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes , 2009, Cancer.
[116] Mary Boulton,et al. The information needs of partners and family members of cancer patients: a systematic literature review. , 2009, Patient education and counseling.
[117] M. Lens,et al. Surgical excision margins for primary cutaneous melanoma. , 2009, The Cochrane database of systematic reviews.
[118] A. Zapf,et al. Cutting a sentinel lymph node into slices is the optimal first step for examination of sentinel lymph nodes in melanoma patients , 2009, Modern Pathology.
[119] H. Einsele,et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. , 2009, European journal of cancer.
[120] M. Blettner,et al. [Psycho-oncological aspects of malignant melanoma. A systematic review from 1990-2008]. , 2009, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.
[121] K. Kroenke,et al. Cancer-related fatigue and its associations with depression and anxiety: a systematic review. , 2009, Psychosomatics.
[122] M. Mihm,et al. EANM-EORTC general recommendations for sentinel node diagnostics in melanoma , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[123] C. Rasch,et al. Regional control of melanoma neck node metastasis after selective neck dissection with or without adjuvant radiotherapy. , 2009, Archives of otolaryngology--head & neck surgery.
[124] D. Schadendorf,et al. Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B , 2009, Clinical Cancer Research.
[125] A. Hauschild,et al. Surgery and radiotherapy in the treatment of cutaneous melanoma , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[126] J. Coebergh,et al. A systematic review of health-related quality of life in cutaneous melanoma , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[127] E. Bastiaannet,et al. S-100B Concentrations Predict Disease-Free Survival in Stage III Melanoma Patients , 2009, Annals of Surgical Oncology.
[128] G. Manda,et al. Serum markers in skin melanoma--preliminary study. , 2009, Roumanian archives of microbiology and immunology.
[129] A. Eggermont,et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). , 2009, European journal of cancer.
[130] C. Shields,et al. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. , 2009, Radiology.
[131] Zhihai Ma,et al. Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis , 2009, Journal of cutaneous pathology.
[132] B. Melichar,et al. Liver metastases from uveal melanoma: clinical experience of hepatic arterial infusion of cisplatin, vinblastine and dacarbazine. , 2009, Hepato-gastroenterology.
[133] D. Schadendorf,et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[134] E. Bruera,et al. Palliative cancer care a decade later: accomplishments, the need, next steps -- from the American Society of Clinical Oncology. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[135] A. Hauschild,et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[136] Rikke Riber-Hansen,et al. Metastatic melanoma volume in sentinel nodes: objective stereology‐based measurement predicts disease recurrence and survival , 2009, Histopathology.
[137] I. V. D. van der Ploeg,et al. Is Completion Lymph Node Dissection Needed in Case of Minimal Melanoma Metastasis in the Sentinel Node? , 2009, Annals of surgery.
[138] M. Lotem,et al. Long-term survival of uveal melanoma patients after surgery for liver metastases , 2009, British Journal of Ophthalmology.
[139] A. Eggermont,et al. Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[140] R. van Haselen,et al. Homeopathic medicines for adverse effects of cancer treatments. , 2009, The Cochrane database of systematic reviews.
[141] R. Mcgoldrick,et al. Does staging computered tomography change management in thick malignant melanoma? , 2009, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.
[142] Jane M. Young,et al. What are the unmet supportive care needs of people with cancer? A systematic review , 2009, Supportive Care in Cancer.
[143] D. McCready,et al. Lymph node assessment in melanoma , 2009, Journal of surgical oncology.
[144] L. Yap,et al. Lymphadenectomy for Melanoma in the Clinically N1 Neck: Radical, Modified Radical, or Selective? , 2009, The Journal of craniofacial surgery.
[145] R. Scolyer,et al. Surgery for melanoma metastases of the gastrointestinal tract: indications and results. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[146] K. Shannon,et al. Proposed Quality Standards for Regional Lymph Node Dissections in Patients With Melanoma , 2009, Annals of surgery.
[147] Jan Zakrzewski,et al. Meta‐analysis of sentinel lymph node positivity in thin melanoma (≤1 mm) , 2009, Cancer.
[148] A. Marghoob,et al. Costs of the detection of metastases and follow-up examinations in cutaneous melanoma , 2009, Melanoma research.
[149] M. Weichenthal,et al. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse , 2009, Melanoma research.
[150] A. Fritsche,et al. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma , 2009, Melanoma research.
[151] W. Vogel,et al. The Yield of SPECT/CT for Anatomical Lymphatic Mapping in Patients with Melanoma , 2009, Annals of Surgical Oncology.
[152] C. Nutting,et al. A First Report of Radioembolization for Hepatic Metastases From Ocular Melanoma , 2009, Cancer investigation.
[153] S. Payne,et al. Advanced cancer patients’ prognostic information preferences: a review , 2009, Palliative medicine.
[154] G. Arcangeli,et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology , 2009, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[155] P. G. Lang,et al. Desmoplastic Neurotropic Melanoma: A Clinicopathologic Analysis of 128 Cases , 2009 .
[156] P. G. Lang,et al. Detection of First Relapse in Cutaneous Melanoma Patients: Implications for the Formulation of Evidence-Based Follow-up Guidelines , 2009 .
[157] G. Benea,et al. Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. , 2009, In vivo.
[158] C. Benedetti,et al. NCCN clinical practice guidelines in oncology: palliative care. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[159] R. Fisher,et al. Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[160] C. Garbe,et al. Sentinel Lymph Node Dissection in Primary Melanoma Reduces Subsequent Regional Lymph Node Metastasis as Well as Distant Metastasis After Nodal Involvement , 2009, Annals of Surgical Oncology.
[161] E. Carmeli,et al. Retrospective trial of complete decongestive physical therapy for lower extremity secondary lymphedema in melanoma patients , 2009, Supportive Care in Cancer.
[162] G. Carretero,et al. [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2]. , 2009, Actas dermo-sifiliograficas.
[163] M. Brundage,et al. Overall information needs of early-stage prostate cancer patients over a decade: highly variable and remarkably stable , 2009, Supportive Care in Cancer.
[164] J. Craig,et al. The Role of Surveillance Chest X-Rays in the Follow-Up of High-Risk Melanoma Patients , 2009, Annals of Surgical Oncology.
[165] C. Junghanss,et al. Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) , 2009, Annals of Hematology.
[166] T. Beyer,et al. Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[167] A. Komorowski,et al. Stage III Thick (>4.0 mm) Lower Extremity Melanoma: Is Timing of Lymph Node Involvement a Prognostic Factor? , 2009, World Journal of Surgery.
[168] S. Mocellin,et al. Clinical Considerations on Sentinel Node Biopsy in Melanoma from an Italian Multicentric Study on 1,313 Patients (SOLISM–IMI) , 2009, Annals of Surgical Oncology.
[169] P. Hersey,et al. Chemoablation of metastatic melanoma using intralesional Rose Bengal , 2008, Melanoma research.
[170] S. van Dulmen,et al. Does age really matter? Recall of information presented to newly referred patients with cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[171] S. Mocellin,et al. The prognostic value of serum S100B in patients with cutaneous melanoma: A meta‐analysis , 2008, International journal of cancer.
[172] Clay J Cockerell,et al. Biopsy of the pigmented lesion--when and how. , 2008, Journal of the American Academy of Dermatology.
[173] S. Martinez,et al. A rational surgical approach to the treatment of distant melanoma metastases. , 2008, Cancer treatment reviews.
[174] S. Soong,et al. Follow‐up schedules after treatment for malignant melanoma , 2008, The British journal of surgery.
[175] A. Hauschild,et al. Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group , 2008, Melanoma research.
[176] T. Tüting,et al. Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma , 2008, Melanoma research.
[177] S. Fukui,et al. A randomized study assessing the efficacy of communication skill training on patients' psychologic distress and coping , 2008, Cancer.
[178] Riccardo Bono,et al. Dermoscopic evaluation of amelanotic and hypomelanotic melanoma. , 2008, Archives of dermatology.
[179] James W. Patterson,et al. Skin Mapping With Punch Biopsies for Defining Margins in Melanoma: When You Don’t Know How Far to Go , 2008, Annals of Surgical Oncology.
[180] D. Morris,et al. Liver resection and cryotherapy for metastatic melanoma. , 2008, International surgery.
[181] P. Rutkowski,et al. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase‐polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level , 2008, The British journal of dermatology.
[182] S. Menzies,et al. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta‐analysis of studies performed in a clinical setting , 2008, The British journal of dermatology.
[183] A. Kielar,et al. PET vs sentinel lymph node biopsy for staging melanoma: a patient intervention, comparison, outcome analysis. , 2008, Journal of the American College of Radiology : JACR.
[184] K. Griffith,et al. Do Micromorphometric Features of Metastatic Deposits Within Sentinel Nodes Predict Nonsentinel Lymph Node Involvement in Melanoma? , 2008, Annals of Surgical Oncology.
[185] A. Hauschild,et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2008, The Lancet.
[186] P. Trask,et al. Psychometric validation of the cancer therapy satisfaction questionnaire. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[187] R. Petersen,et al. Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion , 2008, Annals of Surgical Oncology.
[188] A. Enk,et al. Skin cancer: Follow‐Up, rehabilitation, palliative and supportive care , 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[189] M. Weichenthal,et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[190] P. Ascierto,et al. EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results , 2008 .
[191] K. Courneya,et al. Cancer survivors' adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society's SCS-II. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[192] C. Bokemeyer,et al. Erythropoietins should be used according to guidelines. , 2008, The Lancet. Oncology.
[193] J. Thompson,et al. Detection of second primary cutaneous melanomas. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[194] D. Razavi,et al. Factors that influence cancer patients' and relatives' anxiety following a three‐person medical consultation: impact of a communication skills training program for physicians , 2008, Psycho-oncology.
[195] M. Aapro,et al. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. , 2008, The oncologist.
[196] K. Linde,et al. Mistletoe therapy in oncology. , 2008, The Cochrane database of systematic reviews.
[197] R. Gutzmer,et al. Criteria in Sentinel Lymph Nodes of Melanoma Patients that Predict Involvement of Nonsentinel Lymph Nodes , 2008, Annals of Surgical Oncology.
[198] M. Bilsky,et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. , 2008, Neuro-oncology.
[199] H. Gollnick,et al. Management of primary and metastasized melanoma in Germany in the time period 1976–2005: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society , 2008, Melanoma research.
[200] M. Olausson,et al. Isolated hepatic perfusion for liver metastases of malignant melanoma , 2008, Melanoma research.
[201] M. Foote,et al. DESMOPLASTIC MELANOMA: THE ROLE OF RADIOTHERAPY IN IMPROVING LOCAL CONTROL , 2008, ANZ journal of surgery.
[202] S. Verma,et al. Biochemotherapy for the treatment of metastatic malignant melanoma: a clinical practice guideline , 2008, Current oncology.
[203] U. Kleeberg,et al. Frequency of side effects in outpatient cancer care and their influence on patient satisfaction—a prospective survey using the PASQOC® questionnaire , 2008, Supportive Care in Cancer.
[204] R. Gutzmer,et al. Sentinel lymph node status is the most important prognostic factor for thick (≥ 4 mm) melanomas , 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[205] T. Einarson,et al. Advanced cutaneous malignant melanoma: a systematic review of economic and quality-of-life studies. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[206] D. Morton,et al. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[207] M. Forsting,et al. Zerebrales MRT bei neurologisch asymptomatischen Patienten mit malignem Melanom , 2007, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.
[208] H. Haenssle,et al. Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection , 2008, Melanoma research.
[209] L. Bastholt,et al. A phase II study of thalidomide in patients with brain metastases from malignant melanoma , 2008, Acta oncologica.
[210] R. Scolyer,et al. Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients , 2007, Histopathology.
[211] G. Linette,et al. Hepatic arterial chemoembolization for management of metastatic melanoma. , 2008, AJR. American journal of roentgenology.
[212] K. Shannon,et al. Adjuvant Postoperative Radiotherapy to the Cervical Lymph Nodes in Cutaneous Melanoma: Is There Any Benefit for High-Risk Patients? , 2008, Annals of Surgical Oncology.
[213] G. Hortobagyi,et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[214] A D Oxman,et al. Randomisation to protect against selection bias in healthcare trials. , 2011, The Cochrane database of systematic reviews.
[215] U. Kleeberg,et al. Patient satisfaction in outpatient cancer care: a prospective survey using The PASQOC® questionnaire , 2008, Supportive Care in Cancer.
[216] Deborah Schrag,et al. Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[217] A. Eggermont,et al. Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma , 2007, The British journal of surgery.
[218] U. Hengge,et al. Cost‐effectiveness of reduced follow‐up in malignant melanoma , 2007, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[219] Steven F. Morris,et al. The Diagnostic Accuracy of in vivo Confocal Scanning Laser Microscopy Compared to Dermoscopy of Benign and Malignant Melanocytic Lesions: A Prospective Study , 2007, Dermatology.
[220] M. Mazumdar,et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b‐T3b melanoma , 2007, Cancer.
[221] J. Wolchok,et al. Stage-IV Melanoma and Pulmonary Metastases: Factors Predictive of Survival , 2007, Annals of Surgical Oncology.
[222] R. Gutzmer,et al. Prognostic Significance of Isolated HMB45 or Melan A Positive Cells in Melanoma Sentinel Lymph Nodes , 2007, The American journal of surgical pathology.
[223] N. Aaronson,et al. The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[224] Thomas F Hany,et al. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. , 2007, Radiology.
[225] L. Thomas,et al. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection , 2007, The British journal of dermatology.
[226] Josep Malvehy,et al. Dermoscopy report: proposal for standardization. Results of a consensus meeting of the International Dermoscopy Society. , 2007, Journal of the American Academy of Dermatology.
[227] R. Elashoff,et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites , 2007 .
[228] M. Lebwohl,et al. Patient education and regular surveillance results in earlier diagnosis of second primary melanoma , 2007, International journal of dermatology.
[229] S. Wyke,et al. Designing an integrated follow-up programme for people treated for cutaneous malignant melanoma: a practical application of the MRC framework for the design and evaluation of complex interventions to improve health. , 2007, Family practice.
[230] A. Hauschild,et al. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. , 2007, European Journal of Surgical Oncology.
[231] J. Lumbroso,et al. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm , 2007, Melanoma research.
[232] D. Tripathy,et al. Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. , 2007, The Cochrane database of systematic reviews.
[233] Z. Solomon,et al. Objective and subjective stressors and the psychological adjustment of melanoma survivors , 2007, Psycho-oncology.
[234] Stanley J. Miller,et al. Mohs Surgery for the Treatment of Melanoma in Situ: A Review , 2007, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
[235] C. Lebbé,et al. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. , 2007, European journal of cancer.
[236] K. Bjordal,et al. EORTC QLQ‐INFO26: a questionnaire to assess information given to cancer patients a preliminary analysis in eight countries , 2007, Psycho-oncology.
[237] H. Macapinlac,et al. Evaluation and localization of lymphatic drainage and sentinel lymph nodes in patients with head and neck melanomas by hybrid SPECT/CT lymphoscintigraphic imaging. , 2007, Journal of nuclear medicine technology.
[238] E. von Kardorff,et al. [Which information relatives of patients with cancer are searching for? Are the findings helpful for coping and care?]. , 2007, Medizinische Klinik.
[239] A. Dalgleish,et al. Phase I/II study of topical imiquimod and intralesional interleukin‐2 in the treatment of accessible metastases in malignant melanoma , 2007, The British journal of dermatology.
[240] C. Claussen,et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. , 2007, European journal of cancer.
[241] B. Higgins,et al. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. , 2007, The Cochrane database of systematic reviews.
[242] Suephy C. Chen,et al. Interferon Alfa‐2b or Not 2b? Significant Differences Exist in the Decision‐Making Process between Melanoma Patients Who Accept or Decline High‐Dose Adjuvant Interferon Alfa‐2b Treatment , 2007, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
[243] J. Larkin,et al. A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma , 2006, British Journal of Cancer.
[244] D. Morton,et al. Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanomas? , 2000, Annals of Surgical Oncology.
[245] B. Thiers. Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group , 2007 .
[246] A. Oxman,et al. Outcomes of patients who participate in randomised controlled trials compared to similar patients receiving similar interventions who do not participate. , 2007, The Cochrane database of systematic reviews.
[247] D. Harpole,et al. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. , 2007, The Journal of thoracic and cardiovascular surgery.
[248] L. Cohen,et al. Discussing complementary therapies in an oncology setting. , 2007, Journal of the Society for Integrative Oncology.
[249] D. Reintgen,et al. Regional node dissection for melanoma: techniques and indication. , 2007, Surgical oncology clinics of North America.
[250] C. Bokemeyer,et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. , 2007, European journal of cancer.
[251] K. Busam,et al. Primary Cutaneous Melanoma with Regression Does not Require a Lower Threshold for Sentinel Lymph Node Biopsy , 2007, Annals of Surgical Oncology.
[252] V. Sondak,et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma , 2007, Cancer.
[253] D. Schadendorf,et al. Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group , 2007, Journal of Cancer Research and Clinical Oncology.
[254] D. Morton,et al. Natural History of Melanoma in 773 Patients with Tumor-Negative Sentinel Lymph Nodes , 2007, Annals of Surgical Oncology.
[255] H. Norton,et al. Method of Biopsy and Incidence of Positive Margins in Primary Melanoma , 2007, Annals of Surgical Oncology.
[256] S. Zangos,et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival , 2007, Journal of Cancer Research and Clinical Oncology.
[257] J. Marsden,et al. Melanoma histopathology reporting: are we complying with the National Minimum Dataset? , 2006, Journal of Clinical Pathology.
[258] Glyn Elwyn,et al. Inside the black box of shared decision making: distinguishing between the process of involvement and who makes the decision , 2006, Health expectations : an international journal of public participation in health care and health policy.
[259] R P Braun,et al. Dermoscopy Key Points: Recommendations from the International Dermoscopy Society , 2006, Dermatology.
[260] Cecelia E Schmalbach,et al. The management of head and neck melanoma. , 2006, Current problems in surgery.
[261] A. Hauschild,et al. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[262] A. Eggermont,et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[263] R. Elashoff,et al. Sentinel-node biopsy or nodal observation in melanoma. , 2006, The New England journal of medicine.
[264] L. Fallowfield,et al. Information needs and experiences: an audit of UK cancer patients. , 2006, European journal of oncology nursing : the official journal of European Oncology Nursing Society.
[265] L. von Essen,et al. Is doctors' ability to identify cancer patients' worry and wish for information related to doctors' self-efficacy with regard to communicating about difficult matters? , 2006, European journal of cancer care.
[266] Iris Zalaudek,et al. Why perform dermoscopy? The evidence for its role in the routine management of pigmented skin lesions. , 2006, Archives of dermatology.
[267] Jeffrey E. Lee,et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[268] C. Bartoli,et al. Micro‐melanoma detection: a clinical study on 206 consecutive cases of pigmented skin lesions with a diameter ≤ 3 mm , 2006, The British journal of dermatology.
[269] S. Menzies,et al. Identification of clinically featureless incipient melanoma using sequential dermoscopy imaging. , 2006, Archives of dermatology.
[270] H. Bertsch,et al. Factors Predicting the Risk of In-Transit Recurrence After Sentinel Lymphonodectomy in Patients With Cutaneous Malignant Melanoma , 2006, Annals of Surgical Oncology.
[271] S. Manne,et al. Prevalence and Correlates of Sun Protection and Skin Self-Examination Practices Among Cutaneous Malignant Melanoma Survivors , 2006, Journal of Behavioral Medicine.
[272] Josef Smolle,et al. Sensitivity and specificity of confocal laser‐scanning microscopy for in vivo diagnosis of malignant skin tumors , 2006, Cancer.
[273] Thomas J. Smith,et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[274] A. Cantor,et al. Survival after surgical resection of isolated pulmonary metastases from malignant melanoma. , 2006, Cancer control : journal of the Moffitt Cancer Center.
[275] J. Grob,et al. Randomized Controlled Study of Electrochemotherapy in the Local Treatment of Skin Metastases of Melanoma , 2006, Journal of cutaneous medicine and surgery.
[276] D. Morton,et al. Can Surgical Therapy Alone Achieve Long‐Term Cure of Melanoma Metastatic to Regional Nodes? , 2006, Cancer journal.
[277] G. Fogarty,et al. The utility of magnetic resonance imaging in the detection of brain metastases in the staging of cutaneous melanoma. , 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).
[278] H. Haenssle,et al. Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma. , 2006, The Journal of investigative dermatology.
[279] Daniela Massi,et al. Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[280] L Edler,et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[281] D. McCready,et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma , 2006, Cancer.
[282] R. Stupp,et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[283] T. Pawlik,et al. Hepatic Resection for Metastatic Melanoma: Distinct Patterns of Recurrence and Prognosis for Ocular Versus Cutaneous Disease , 2006, Annals of Surgical Oncology.
[284] Kalyani Ankem,et al. Factors influencing information needs among cancer patients: A meta-analysis , 2006 .
[285] K. Dietz,et al. Conventional histology vs. three‐dimensional histology in lentigo maligna melanoma , 2006, The British journal of dermatology.
[286] E. Levine,et al. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. , 2006, Archives of surgery.
[287] T. Nägele,et al. Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. , 2006, European journal of cancer.
[288] S. Dixon,et al. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial , 2006, British Journal of Cancer.
[289] J. Malvehy,et al. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case–control study , 2006, Journal of Clinical Pathology.
[290] B. Balda,et al. Sentinel lymphonodectomy and S-classification: A successful strategy for better prediction and improvement of outcome of melanoma , 2004, Annals of Surgical Oncology.
[291] A. Bartolucci,et al. Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial , 1996, Annals of Surgical Oncology.
[292] U. Leiter,et al. Sozialmedizinische Maßnahmen nach Melanomdiagnose , 2006 .
[293] P. G. Lang,et al. Sentinel Node Biopsy for Early-Stage Melanoma: Accuracy and Morbidity in MSLT-I, an International Multicenter Trial , 2006 .
[294] P. Leboit. Pathology and genetics of skin tumours , 2006 .
[295] N. Favre,et al. Communication skills training in oncology: it works! , 2006, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[296] C. Warneke,et al. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. , 2006, The Journal of investigative dermatology.
[297] A. Vickers,et al. Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. , 2006, The Cochrane database of systematic reviews.
[298] D. Reintgen,et al. Multiple primary melanomas: Implications for screening and follow-up programs for melanoma , 2006, Annals of Surgical Oncology.
[299] M. Machado,et al. Selected Patients with Metastatic Melanoma May Benefit from Liver Resection , 2006, World Journal of Surgery.
[300] M. Ross,et al. Is incisional biopsy of melanoma harmful? , 2005, American journal of surgery.
[301] M Rajadhyaksha,et al. Multimodal in vivo optical imaging, including confocal microscopy, facilitates presurgical margin mapping for clinically complex lentigo maligna melanoma , 2005, The British journal of dermatology.
[302] L. Degner,et al. The communication goals and needs of cancer patients: a review , 2005, Psycho-oncology.
[303] V. Sondak,et al. Sentinel node biopsy for thin melanomas: which patients should be considered? , 2005, Cancer control : journal of the Moffitt Cancer Center.
[304] M. Sabel,et al. Wide excision without radiation for desmoplastic melanoma , 2005, Cancer.
[305] R. Fainsinger,et al. A validation study of a pain classification system for advanced cancer patients using content experts: the Edmonton Classification System for Cancer Pain , 2005, Palliative medicine.
[306] A. Hauschild,et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes , 2005, Modern Pathology.
[307] A. Francken,et al. Follow-up in patients with localised primary cutaneous melanoma. , 2005, The Lancet. Oncology.
[308] S. Emmert,et al. [Intraoperative detection of sentinel lymph nodes in cutaneous malignant melanoma -- blue dye alone versus blue dye plus gamma detection]. , 2005, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[309] C. Shields,et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study , 2005, Melanoma research.
[310] R. Wolfe,et al. Comparative performance of 4 dermoscopic algorithms by nonexperts for the diagnosis of melanocytic lesions. , 2005, Archives of dermatology.
[311] H. D. de Haes,et al. Communication in palliative care: a review of recent literature , 2005, Current opinion in oncology.
[312] J. Menell,et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma , 2005, Cancer.
[313] A. Oxman,et al. Systematic review to determine whether participation in a trial influences outcome , 2005, BMJ : British Medical Journal.
[314] P. Rutkowski,et al. Quality‐of‐Life Evaluation in an Interferon Therapy After Radical Surgery in Cutaneous Melanoma Patients , 2005, Cancer nursing.
[315] J. Malvehy,et al. S-100beta and MIA in advanced melanoma in relation to prognostic factors. , 2005, Anticancer research.
[316] P. V. D. Maas,et al. Information needs of patients with incurable cancer , 2005, Supportive Care in Cancer.
[317] Richard A. Anderson,et al. Fertility preservation for young patients with cancer: who is at risk and what can be offered? , 2005, The Lancet. Oncology.
[318] A. Dancey,et al. Views of UK melanoma patients on routine follow-up care. , 2005, British journal of plastic surgery.
[319] Cesare Massone,et al. Diagnostic applicability of in vivo confocal laser scanning microscopy in melanocytic skin tumors. , 2005, The Journal of investigative dermatology.
[320] M. Gonen,et al. Characterization of Micrometastatic Disease in Melanoma Sentinel Lymph Nodes by Enhanced Pathology: Recommendations for Standardizing Pathologic Analysis , 2005, The American journal of surgical pathology.
[321] D. Cella,et al. Measuring quality of life in patients with melanoma: development of the FACT-melanoma subscale. , 2005, The journal of supportive oncology.
[322] B. Thomsen,et al. Psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[323] E. Bastiaannet,et al. Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications. , 2005, Cancer treatment reviews.
[324] P. Hersey,et al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy) , 2005, Melanoma research.
[325] A. Munro,et al. Chinese medical herbs for chemotherapy side effects in colorectal cancer patients. , 2005, The Cochrane database of systematic reviews.
[326] E. Steels,et al. Evaluation of extensive initial staging procedure in intermediate/high‐risk melanoma patients , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.
[327] C. O'brien,et al. Neck dissection for cutaneous malignant melanoma , 1992, World Journal of Surgery.
[328] R. Smalley,et al. Hyperthermic perfusion with chemotherapy for melanoma of the extremities , 1989, World Journal of Surgery.
[329] N. Buhles,et al. [Dermato-oncological rehabilitation]. , 2005, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.
[330] M. McCarter,et al. Identifying risk factors for complications following sentinel lymph node biopsy for melanoma. , 2005, Archives of surgery.
[331] A. Werner,et al. Aufklärung und Begleitung von Tumorpatienten , 2005, Der Onkologe.
[332] A. Dhar,et al. National Institute for Health and Clinical Excellence , 2005 .
[333] U. Kleeberg,et al. Patient satisfaction and quality of life in cancer outpatients: results of the PASQOC* study , 2005, Supportive Care in Cancer.
[334] B. Powell,et al. Contraindications to sentinel lymph node biopsy in cutaneous malignant melanoma. , 2004, British journal of plastic surgery.
[335] R. Scolyer,et al. Sentinel lymph nodes in malignant melanoma: Extended histopathologic evaluation improves diagnostic precision , 2004, Cancer.
[336] A. Tres,et al. Prognostic Value of Serum S-100B in Malignant Melanoma , 2004, Tumori.
[337] A. Beauchet,et al. Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis. , 2004, The Lancet. Oncology.
[338] R. Scolyer,et al. Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. , 2004, American journal of clinical pathology.
[339] Jennifer L. Schwartz,et al. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. , 2004, Journal of the American Academy of Dermatology.
[340] M. Green,et al. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[341] O. Belvedere,et al. Information given to cancer patients on diagnosis, prognosis and treatment: the clinical oncologist's perspective. , 2004, European journal of cancer.
[342] B. Redman,et al. Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon , 2004, Psycho-oncology.
[343] M. Eisemann,et al. Development of a questionnaire to evaluate the information needs of cancer patients: the EORTC questionnaire. , 2004, Patient education and counseling.
[344] H. Gogas,et al. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma , 2004, Melanoma research.
[345] T. Lehnert,et al. Recognition of distress and psychiatric morbidity in cancer patients: a multi-method approach. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[346] I. Higginson,et al. Communication training for health professionals who care for patients with cancer: a systematic review of effectiveness , 2004, Supportive Care in Cancer.
[347] Hao Wang,et al. Sun protection and skin surveillance practices among relatives of patients with malignant melanoma: prevalence and predictors. , 2004, Preventive medicine.
[348] L. Mack,et al. Controversies in the management of metastatic melanoma to regional lymphatic basins , 2004, Journal of surgical oncology.
[349] M. Gore,et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[350] J. Kirkwood,et al. Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver , 2004, Melanoma research.
[351] F. Tas,et al. Clinical Value of Protein S100 and Melanoma-Inhibitory Activity (MIA) in Malignant Melanoma , 2004, American Journal of Clinical Oncology.
[352] J. Thomas,et al. Management of in‐transit metastases from cutaneous malignant melanoma , 2004, The British journal of surgery.
[353] P. V. van Diest,et al. Sentinel lymph node investigation in melanoma: detailed analysis of the yield from step sectioning and immunohistochemistry , 2004, Journal of Clinical Pathology.
[354] Paolo Carli,et al. Addition of dermoscopy to conventional naked-eye examination in melanoma screening: a randomized study. , 2004, Journal of the American Academy of Dermatology.
[355] D. Tripathy,et al. Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[356] H. Cody,et al. A Prospective Analysis of the Effect of Blue-Dye Volume on Sentinel Lymph Node Mapping Success and Incidence of Allergic Reaction in Patients With Breast Cancer , 2004, Annals of Surgical Oncology.
[357] D. Neuberg,et al. Mature results of a phase III randomized trial of bacillus Calmette–Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I–III melanoma (E1673) , 2004, Cancer.
[358] A. Marghoob,et al. Clinical and Laboratory Investigations Melanomas detected with the aid of total cutaneous photography , 2004 .
[359] R. Dummer,et al. Baseline staging in cutaneous malignant melanoma , 2004, The British journal of dermatology.
[360] P. Carli,et al. Improvement of malignant/benign ratio in excised melanocytic lesions in the ‘dermoscopy era’: a retrospective study 1997–2001 , 2004, The British journal of dermatology.
[361] W. Jurecka,et al. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II , 2004, Melanoma research.
[362] K. Shannon,et al. Determinants of outcome in melanoma patients with cerebral metastases. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[363] M. Weichenthal,et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[364] S. Barni,et al. Effects of media information on cancer patients' opinions, feelings, decision‐making process and physician‐patient communication , 2004, Cancer.
[365] J. Barrett,et al. A quality-of-life study in high-risk (thickness > = or 2 mm) cutaneous melanoma patients in a randomized trial of 1-cm versus 3-cm surgical excision margins. , 2004, The journal of investigative dermatology. Symposium proceedings.
[366] C. Mélot,et al. Interferon Alpha as Adjuvant Postsurgical Treatment of Melanoma: A Meta-Analysis , 2004, Dermatology.
[367] M. Martini. An Atlas of Surface Microscopy of Pigmented Skin Lesions: Dermoscopy, 2nd ed , 2004 .
[368] R. Tollenaar,et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver , 2004, Melanoma research.
[369] L. Fallowfield,et al. Communicating sad, bad, and difficult news in medicine , 2004, The Lancet.
[370] P. Butow,et al. Patterns over time in quality of life, coping and psychological adjustment in late stage melanoma patients: An application of multilevel models , 2000, Quality of Life Research.
[371] M. Sullivan,et al. The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique , 1993, Quality of Life Research.
[372] H. C. Müller-busch. [Sedation in end-of-life care - ethical aspects]. , 2004, Deutsche medizinische Wochenschrift.
[373] A. Kopf,et al. Detection of melanomas in patients followed up with total cutaneous examinations, total cutaneous photography, and dermoscopy. , 2004, Journal of the American Academy of Dermatology.
[374] M. Gore,et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[375] C. Garbe,et al. [Therapy of malignant melanoma at the stage of distant metastasis]. , 2004, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.
[376] C. Garbe,et al. Risk estimation for malignant transformation of melanocytic nevi. , 2004, Archives of dermatology.
[377] June K Robinson,et al. Digital epiluminescence microscopy monitoring of high-risk patients. , 2004, Archives of dermatology.
[378] R. Scolyer,et al. Ultrasound Examination of Sentinel Nodes in the Initial Assessment of Patients With Primary Cutaneous Melanoma , 2004, Annals of Surgical Oncology.
[379] C. Jacquillat,et al. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma , 2004, Cancer Chemotherapy and Pharmacology.
[380] A. Sober,et al. Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival. , 2004, Archives of dermatology.
[381] S. Steinberg,et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[382] C. Garbe,et al. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. , 2003, The Lancet. Oncology.
[383] M. Möhrle. [Micrographic controlled surgery (3D-histology) in cutaneous melanoma]. , 2003, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[384] C. Garbe,et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases , 2003, British Journal of Cancer.
[385] R. Braun,et al. Detection of micrometastases in sentinel lymph nodes from melanoma patients: direct comparison of multimarker molecular and immunopathological methods , 2003, Melanoma research.
[386] A. Rosenberger,et al. [Retrospective study of malignant melanoma patients treated with mistletoe extracts]. , 2003, Forschende Komplementarmedizin und klassische Naturheilkunde = Research in complementary and natural classical medicine.
[387] R. Turner,et al. Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[388] O. Sezer,et al. Antimicrobial therapy of unexplained fever in neutropenic patients , 2003, Annals of Hematology.
[389] E. Even-Sapir,et al. Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[390] D. Razavi,et al. How to optimize physicians' communication skills in cancer care: results of a randomized study assessing the usefulness of posttraining consolidation workshops. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[391] Jennifer L. Schwartz,et al. Cognitive‐behavioral intervention for distress in patients with melanoma , 2003, Cancer.
[392] M. Gore,et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. , 2003, Cancer treatment reviews.
[393] M. Ranson,et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[394] A. Eggermont,et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma , 2003, The Journal of pathology.
[395] Anthony L Back,et al. Teaching communication skills to medical oncology fellows. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[396] T. Calcaterra,et al. Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma , 2003, Head & neck.
[397] M. Bailey,et al. Radical lymph node dissection for melanoma , 2003, ANZ journal of surgery.
[398] Jennifer L. Schwartz,et al. Current management of patients with melanoma who are pregnant, want to get pregnant, or do not want to get pregnant , 2003, Cancer.
[399] A. Kneier. Coping with melanoma--ten strategies that promote psychological adjustment. , 2003, The Surgical clinics of North America.
[400] C. Garbe,et al. “Functional” Surgery in Subungual Melanoma , 2003, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
[401] Vincenzo De Giorgi,et al. The problem of false‐positive diagnosis in melanoma screening: the impact of dermoscopy , 2003, Melanoma research.
[402] C. Garbe,et al. Diagnostic value and prognostic significance of protein S‐100β, melanoma‐inhibitory activity, and tyrosinase/MART‐1 reverse transcription‐polymerase chain reaction in the follow‐up of high‐risk melanoma patients , 2003, Cancer.
[403] A. Khorana,et al. A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma , 2003, Cancer Gene Therapy.
[404] Yuting Zhang,et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma , 2003, Cancer.
[405] D. McCready,et al. Previous wide local excision of primary melanoma is not a contraindication for sentinel lymph node biopsy of the trunk and extremity , 2003, Journal of surgical oncology.
[406] W. Goggins,et al. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. , 2003, Archives of dermatology.
[407] A. Hauschild,et al. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma , 2003, Melanoma research.
[408] A. Blum,et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[409] Hensin Tsao,et al. A population‐based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors , 2003, Cancer.
[410] M. Middleton,et al. Health-Related Quality of Life in Patients with Advanced Metastatic Melanoma: Results of a Randomized Phase III Study Comparing Temozolomide with Dacarbazine , 2003, Cancer investigation.
[411] U. Koch,et al. Empfehlungen zur Psychoonkologischen Versorgung im Akutkrankenhaus , 2003 .
[412] L. From,et al. Characterizing anxiety in melanoma patients. , 2003, Journal of cutaneous medicine and surgery.
[413] L. Frati,et al. Prognostic Significance of Reverse Transcriptase-Polymerase Chain Reaction–Negative Sentinel Nodes in Malignant Melanoma , 2003, Annals of Surgical Oncology.
[414] F. Fawzy,et al. Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up. , 2003, Archives of general psychiatry.
[415] P. Butow,et al. Psychological responses of patients receiving a diagnosis of cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[416] T. Kaptchuk,et al. Advising Patients Who Seek Complementary and Alternative Medical Therapies for Cancer , 2002, Annals of Internal Medicine.
[417] R. Gutzmer,et al. Specificity of tyrosinase and HMB45 PCR in the detection of melanoma metastases in sentinel lymph node biopsies , 2002, Histopathology.
[418] A. Hutchinson,et al. Research methods used in developing and applying quality indicators in primary care , 2002, BMJ : British Medical Journal.
[419] R. Simes,et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[420] D. Schadendorf,et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2 , 2002, British Journal of Cancer.
[421] D. Podoloff,et al. Procedure guideline for lymphoscintigraphy and the use of intraoperative gamma probe for sentinel lymph node localization in melanoma of intermediate thickness 1.0. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[422] L. Thomas,et al. Dermoscopic examination of nail pigmentation. , 2002, Archives of dermatology.
[423] P. Parker,et al. Quality of life in patients with malignant melanoma participating in a phase I trial of an autologous tumour-derived vaccine , 2002, Melanoma research.
[424] S. Ariyan,et al. Preservation of muscle fascia to decrease lymphedema after complete axillary and ilioinguinofemoral lymphadenectomy for melanoma. , 2002, Journal of the American College of Surgeons.
[425] A. Bosserhoff,et al. Elevated MIA serum levels are predictors of poor prognosis after surgical resection of metastatic malignant melanoma. , 2002, Oncology reports.
[426] J. Kirkwood,et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[427] P. Dupont,et al. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact , 2002, Melanoma research.
[428] D. Schadendorf,et al. Primary staging and follow-up in melanoma patients – monocenter evaluation of methods, costs and patient survival , 2002, British Journal of Cancer.
[429] G Rassner,et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma , 2002, The British journal of dermatology.
[430] B. Bonnekoh,et al. Imiquimod, a Topical Immune Response Modifier, in the Treatment of Cutaneous Metastases of Malignant Melanoma , 2002, Dermatology.
[431] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[432] R. Dummer,et al. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X‐rays , 2002, The British journal of dermatology.
[433] E. Brähler,et al. Repräsentativbefragung der deutschen Bevölkerung zu Aufklärungswunsch und Patientenverfügung bei unheilbarer Krankheit , 2002 .
[434] G. Maskarinec,et al. Communication between physicians and cancer patients about complementary and alternative medicine: exploring patients' perspectives , 2002, Psycho-oncology.
[435] C. Shea,et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. , 2002, Archives of dermatology.
[436] P. Wiffen,et al. Bisphosphonates for the relief of pain secondary to bone metastases. , 2002, The Cochrane database of systematic reviews.
[437] V. Sondak,et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[438] J. Lee,et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[439] V. Sondak,et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[440] M. Lens,et al. Elective lymph node dissection in patients with melanoma: systematic review and meta-analysis of randomized controlled trials. , 2002, Archives of surgery.
[441] W. Chiu,et al. Cancer Patients' Desires for Communication of Prognosis Information , 2002, Health communication.
[442] M. Lens,et al. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[443] H. Kittler,et al. Diagnostic accuracy of dermoscopy. , 2002, The Lancet. Oncology.
[444] Lesley Fallowfield,et al. Efficacy of a Cancer Research UK communication skills training model for oncologists: a randomised controlled trial , 2002, The Lancet.
[445] V. Katz,et al. Focus on Primary Care: From Nevus to Neoplasm: Myths of Melanoma in Pregnancy , 2002, Obstetrical & gynecological survey.
[446] D. Coit,et al. Value of Frozen-Section Analysis of Sentinel Lymph Nodes for Primary Cutaneous Malignant Melanoma , 2002, Annals of surgery.
[447] J. Medina,et al. Current Management of Cutaneous Malignant Melanoma of the Head and Neck , 2002, Acta oto-laryngologica.
[448] Aldo Bonoa Cesare Bartolib Natale Cascinellic Manuela Lualdid,et al. A Prospective Study Comparing Diagnosis with the Naked Eye, Dermatoscopy and Telespectrophotometry , 2002 .
[449] G. Strittmatter,et al. How to identify patients in need of psychological intervention. , 2002, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[450] M. Andrykowski,et al. Communication in the cancer ‘bad news’ consultation: patient perceptions and psychological adjustment , 2002, Psycho-oncology.
[451] N. Dalay,et al. Prognostic significance of melanoma inhibiting activity levels in malignant melanoma , 2001, Melanoma research.
[452] D. Tripathy,et al. Lack of adherence with the analgesic regimen: a significant barrier to effective cancer pain management. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[453] S. Menzies,et al. Short-term digital surface microscopic monitoring of atypical or changing melanocytic lesions. , 2001, Archives of dermatology.
[454] D. McCready,et al. Sentinel lymph-node biopsy after previous wide local excision for melanoma. , 2001, Canadian journal of surgery. Journal canadien de chirurgie.
[455] J Dvorák,et al. Intraarterial chemotherapy of malignant melanoma metastatic to the liver. , 2001, Hepato-gastroenterology.
[456] J. Ptacek,et al. Patients' perceptions of receiving bad news about cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[457] P. Aegerter,et al. Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. , 2001, Archives of dermatology.
[458] N. Cascinelli,et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial , 2001, The Lancet.
[459] M. Nosrati,et al. Vascular involvement in the prognosis of primary cutaneous melanoma. , 2001, Archives of dermatology.
[460] N Cascinelli,et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[461] M. Ross,et al. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. , 2001, Surgery.
[462] D. Morton,et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. , 2001, Archives of surgery.
[463] D. Roses,et al. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[464] W. Sterry,et al. Efficacy of ultrasound B‐scan compared with physical examination in follow‐up of melanoma patients , 2001, Cancer.
[465] Hong Wang,et al. A micromorphometry‐based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma , 2001, Cancer.
[466] S. Hayasaka,et al. Psychosocial characteristics of individuals with non-stage IV melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[467] V. Sondak,et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[468] M. Gore,et al. Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study , 2001, British Journal of Cancer.
[469] D. Morton,et al. Earlier diagnosis of second primary melanoma confirms the benefits of patient education and routine postoperative follow‐up , 2001, Cancer.
[470] A. Paccagnella,et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients , 2001, Melanoma research.
[471] W. Baile,et al. Breaking bad news about cancer: patients' preferences for communication. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[472] P. Butow,et al. Hearing the bad news of a cancer diagnosis: the Australian melanoma patient's perspective. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[473] U. Leiter,et al. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. , 2001, Anticancer research.
[474] G. Botti,et al. Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[475] T. Lehnert,et al. Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients , 2001, International Journal of Clinical Oncology.
[476] C. Garbe,et al. Should adjuvant radiotherapy be recommended following resection of regional lymph node metastases of malignant melanomas? , 2001, The British journal of dermatology.
[477] J. Saul,et al. Information needs of patients with cancer: results from a large study in UK cancer centres , 2001, British Journal of Cancer.
[478] J. Dunn,et al. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. , 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).
[479] W. Gillanders,et al. Melanoma thickness and histology predict sentinel lymph node status. , 2001, American journal of surgery.
[480] W. Söllner,et al. [The validity of the Hornheide questionnaire for psychosocial support in skin tumor patients: a survey in an Austrian and German outpatient population with melanoma]. , 2001, Psychotherapie, Psychosomatik, medizinische Psychologie.
[481] C. Balch. New melanoma staging system , 2001, Journal of the National Cancer Institute.
[482] J. Manola,et al. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[483] S. Menzies,et al. Increase in the sensitivity for melanoma diagnosis by primary care physicians using skin surface microscopy , 2000, The British journal of dermatology.
[484] A. Bosserhoff,et al. MIA as a reliable tumor marker in the serum of patients with malignant melanoma. , 2000, Anticancer research.
[485] A. Hauschild,et al. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients. , 2000, Anticancer research.
[486] A. Blum,et al. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence? , 2000, Melanoma research.
[487] M. Rols,et al. Electrochemotherapy of cutaneous metastases in malignant melanoma , 2000, Melanoma research.
[488] W. Stolz,et al. Comparison of Two Prognostic Markers for Malignant Melanoma: MIA and S100 β , 2000, Tumor Biology.
[489] F B Lammes,et al. Doctor-patient communication and cancer patients' quality of life and satisfaction. , 2000, Patient education and counseling.
[490] G. Plewig,et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. , 2000, Journal of the American Academy of Dermatology.
[491] P. Rocmans,et al. Lung metastases from melanoma: when is surgical treatment warranted? , 2000, British Journal of Cancer.
[492] J. Kirkwood,et al. Cognitive Function and Quality of Life in Interferon Therapy for Melanoma , 2000, Clinical nursing research.
[493] W. Baile,et al. SPIKES-A six-step protocol for delivering bad news: application to the patient with cancer. , 2000, The oncologist.
[494] E. Arbit,et al. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. , 2000, Journal of neurosurgery.
[495] V. Sondak,et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[496] C. Garbe,et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. , 2000, The Journal of investigative dermatology.
[497] P. Butow,et al. Communication styles in the cancer consultation: preferences for a patient‐centred approach , 2000, Psycho-oncology.
[498] D. Tyler,et al. Analysis of prognosis and disease progression after local recurrence of melanoma , 2000, Cancer.
[499] D Miklavcic,et al. Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[500] Ignazio Stanganelli,et al. A Cancer-Registry-Assisted Evaluation of the Accuracy of Digital Epiluminescence Microscopy Associated with Clinical Examination of Pigmented Skin Lesions , 2000, Dermatology.
[501] R. Sanson-Fisher,et al. The unmet supportive care needs of patients with cancer. Supportive Care Review Group. , 2000 .
[502] V. Quillien,et al. [Serum S100B protein and stage of cutaneous melanoma: a prospective study]. , 2000, Annales de dermatologie et de venereologie.
[503] R. Sanson-Fisher,et al. The unmet supportive care needs of patients with cancer , 2000, Cancer.
[504] D. Schadendorf,et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[505] C. Berking,et al. S-100 protein in peripheral blood: a marker for melanoma metastases: a prospective 2-center study of 570 patients with melanoma. , 1999, Journal of the American Academy of Dermatology.
[506] Y. Kirova,et al. Radiotherapy as palliative treatment for metastatic melanoma. , 1999, Melanoma research.
[507] S. Ariyan,et al. Follow‐up recommendations for patients with American Joint Committee on Cancer Stages I–III malignant melanoma , 1999, Cancer.
[508] K. Freedberg,et al. Screening for malignant melanoma: A cost-effectiveness analysis. , 1999, Journal of the American Academy of Dermatology.
[509] V. Jenkins,et al. Effective communication skills are the key to good cancer care. , 1999, European journal of cancer.
[510] R. Elashoff,et al. Increased Incidence of Second Primary Melanoma in Patients With a Previous Cutaneous Melanoma , 1999, Annals of Surgical Oncology.
[511] C. Benelli,et al. The dermoscopic versus the clinical diagnosis of melanoma. , 1999, European journal of dermatology : EJD.
[512] C. Begg,et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[513] W. Hohenberger,et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. , 1999, International journal of radiation oncology, biology, physics.
[514] A. Benner,et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[515] S. Adler,et al. Disclosing complementary and alternative medicine use in the medical encounter: a qualitative study in women with breast cancer. , 1999, The Journal of family practice.
[516] J. Thompson,et al. High-resolution ultrasound to diagnose melanoma metastases in patients with clinically palpable lymph nodes. , 1999, Australasian radiology.
[517] R. C. Johnson,et al. Follow‐up of patients with a thin melanoma , 1999, The British journal of surgery.
[518] A. Hart,et al. Positive Iliac and Obturator Nodes in Melanoma: Survival and Prognostic Factors , 1999, Annals of Surgical Oncology.
[519] T. Psaras,et al. Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis. , 1999, Nuclear medicine communications.
[520] S. Steinberg,et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[521] U. Chetty,et al. A rational approach to melanoma follow‐up in patients with primary cutaneous melanoma , 1999, The British journal of dermatology.
[522] S. Libutti,et al. Management of Symptomatic Malignant Melanoma of the Gastrointestinal Tract , 1999, Annals of Surgical Oncology.
[523] D. Morton,et al. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. , 1999, Archives of surgery.
[524] R. Byers. Treatment of the neck in melanoma. , 1998, Otolaryngologic clinics of North America.
[525] T. Hamilton,et al. Multiple primary melanomas. , 1998, Journal of the American Academy of Dermatology.
[526] G. Strittmatter,et al. [Need for psychosocial management of facial and skin tumor patients]. , 1998, Psychotherapie, Psychosomatik, medizinische Psychologie.
[527] A. Eggermont,et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, a , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[528] M. Atkins,et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[529] N. Swanson,et al. Use of chest radiography in the initial evaluation of patients with localized melanoma. , 1998, Archives of dermatology.
[530] A. Coates,et al. Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[531] M. Binder,et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[532] B. Vrouenraets,et al. Toxicity and morbidity of isolated limb perfusion. , 1998, Seminars in surgical oncology.
[533] P. Kam,et al. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. , 1998, Seminars in surgical oncology.
[534] V. Servois,et al. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. , 1998, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[535] N. Cascinelli,et al. Evaluation of clinical efficacy and tolerability of intravenous high dose thymopentin in advanced melanoma patients , 1998, Melanoma research.
[536] M. Montbriand. Abandoning biomedicine for alternate therapies: oncology patients' stories. , 1998, Cancer nursing.
[537] C. Chastang,et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. , 1998, Lancet.
[538] W. Söllner,et al. Need for supportive counselling--the professionals' versus the patients' perspective. A survey in a representative sample of 236 melanoma patients. , 1998, Psychotherapy and psychosomatics.
[539] T. Diepgen,et al. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. , 1998, The British journal of dermatology.
[540] B. Kroon,et al. Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma , 1997, Melanoma research.
[541] V. Gebski,et al. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma , 1997, Head & neck.
[542] H. Soyer,et al. [Standards in histopathologic diagnosis of malignant melanomas. Recommendations of the Working Group of the Central Malignant Melanoma Registry of the German Dermatologic Society]. , 1997, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.
[543] W. Stolz,et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. , 1997, Cancer research.
[544] K. Bland,et al. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial. , 1997, Annals of surgery.
[545] J. Kelly,et al. A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance , 1997, The Medical journal of Australia.
[546] C. Garbe,et al. Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma , 1997, Cancer.
[547] C. Garbe,et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma , 1997, Cancer.
[548] G. Halliday,et al. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. , 1997, The Journal of investigative dermatology.
[549] K Wolff,et al. Epiluminescence microscopy of small pigmented skin lesions: short-term formal training improves the diagnostic performance of dermatologists. , 1997, Journal of the American Academy of Dermatology.
[550] M. Augustin,et al. Bedarf und Motivation zu psychosozialen Interventionen bei Patienten mit malignen Hauttumoren : Psychosomatik , 1997 .
[551] J. Kirkwood,et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[552] D. Morton,et al. Surgical resection for melanoma metastatic to the gastrointestinal tract. , 1996, Archives of surgery.
[553] J. Ptacek,et al. Breaking Bad News: A Review of the Literature , 1996 .
[554] Y. Brandberg,et al. Six-month follow-up of effects of an information programme for patients with malignant melanoma. , 1996, Patient education and counseling.
[555] M. Mihm,et al. Biological activity and clinical efficacy of intravenous high-dose thymopentin in metastatic melanoma patients , 1996, Melanoma research.
[556] J. Wehrmann. [Indications for psychosomatically-oriented dermatologic rehabilitation]. , 1996, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.
[557] M. Sullivan,et al. Quality of life evaluation by the EORTC questionnaire technique in patients with generalized malignant melanoma on chemotherapy. , 1996, Acta oncologica.
[558] D. English,et al. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma? , 1995, Journal of the American Academy of Dermatology.
[559] N. Fawzy. A psychoeducational nursing intervention to enhance coping and affective state in newly diagnosed malignant melanoma patients , 1995, Cancer nursing.
[560] J. Kugler,et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[561] R. Sanson-Fisher,et al. Breaking bad news: consensus guidelines for medical practitioners. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[562] I. Siddiqui. American Academy of Otolaryngology—Head and Neck Surgery , 1995 .
[563] J. Graham,et al. Burnout and psychiatric disorder among cancer clinicians. , 1995, British Journal of Cancer.
[564] H. Zarour,et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. , 1995, Dermatology.
[565] K. Henry,et al. Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival. , 1995, Cancer.
[566] P Bauer,et al. Dermatoscopy: usefulness in the differential diagnosis of cutaneous pigmentary lesions , 1994, Melanoma research.
[567] A. Garden,et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. , 1994, International journal of radiation oncology, biology, physics.
[568] J. Callen,et al. Successful treatment of lentigo maligna and lentigo maligna melanoma with mohs' micrographic surgery aided by rush permanent sections , 1994, Cancer.
[569] H. Soyer,et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. , 1994, The Journal of investigative dermatology.
[570] Sidney Bloch,et al. Psychological morbidity in the families of patients with cancer , 1994 .
[571] G. Fiorentini,et al. Intra-Arterial Hepatic Carboplatin-Based Chemotherapy for Ocular Melanoma Metastatic to the Liver. Report of a Phase II Study , 1994, Tumori.
[572] J. Elwood. Screening for Melanoma and Options For-Its Evaluation , 1994, Journal of medical screening.
[573] W. Dummer,et al. [Videomicroscopy in differential diagnosis of skin tumors and secondary prevention of malignant melanoma]. , 1993, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.
[574] E. Abemayor,et al. The role of radiation therapy in the treatment of head and neck cutaneous melanoma. , 1993, American journal of otolaryngology.
[575] V. Ho,et al. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. , 1993, The Journal of dermatologic surgery and oncology.
[576] M. Mihm,et al. Perinodular injection of thymopentine (TP5) in cutaneous and subcutaneous metastases of melanoma , 1993, Melanoma research.
[577] P. Brandani,et al. First recurrence analysis of 840 cutaneous melanomas: a proposal for a follow-up schedule. , 1993, Tumori.
[578] R. Elashoff,et al. Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. , 1993, Archives of general psychiatry.
[579] R. MacKie,et al. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high-risk groups , 1993, The Lancet.
[580] P. Hersey,et al. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. , 1993, Melanoma research.
[581] S. Ariyan,et al. Data on First Recurrence after Treatment for Malignant Melanoma in a Large Patient Population , 1993, Plastic and reconstructive surgery.
[582] R. Nerlinger,et al. Hyperthermia and radiation in advanced malignant melanoma. , 1993, International journal of radiation oncology, biology, physics.
[583] L. Blumenson,et al. Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma. , 1993, European journal of cancer.
[584] V. L. Hall,et al. Follow-up in stage I cutaneous malignant melanoma: an audit. , 1993, Clinical oncology (Royal College of Radiologists (Great Britain)).
[585] M. Mihm,et al. Multiple primary cutaneous melanomas , 1992, Cancer.
[586] M. Sullivan,et al. Anxiety and depressive symptoms at different stages of malignant melanoma , 1992 .
[587] S. Pyrhönen,et al. The use of large fractions in radiotherapy for malignant melanoma. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[588] C. Garbe,et al. Epidemiologic evidence for the role of melanocytic nevi as risk markers and direct precursors of cutaneous malignant melanoma. Results of a case control study in melanoma patients and nonmelanoma control subjects. , 1992, Journal of the American Academy of Dermatology.
[589] D L Morton,et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.
[590] S. George,et al. Analysis of 945 cases of pulmonary metastatic melanoma. , 1992, The Journal of thoracic and cardiovascular surgery.
[591] P. Kaufmann,et al. [Tumor follow-up using sonography and computed tomography in the abdominal region of patients with malignant melanoma]. , 1992, Aktuelle Radiologie.
[592] A. Coates,et al. Cerebral metastases from malignant melanoma. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[593] G. Rassner,et al. [Intralesional therapy of melanoma metastases with recombinant interferon-beta]. , 1992, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.
[594] R. Elashoff,et al. Improved Long-term Survival After Lymphadenectomy of Melanoma Metastatic to Regional Nodes , 1991 .
[595] C. Jacquillat,et al. Fotemustine (S 10036) in the Intra‐Arterial Treatment of Liver Metastasis from Malignant Melanoma: A Phase II Study , 1991, American journal of clinical oncology.
[596] C. O'brien,et al. Experience with 998 cutaneous melanomas of the head and neck over 30 years. , 1991, American journal of surgery.
[597] C. Falkson,et al. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[598] G. Halliday,et al. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. , 1991, The Journal of investigative dermatology.
[599] J E Medina,et al. Standardizing neck dissection terminology. Official report of the Academy's Committee for Head and Neck Surgery and Oncology. , 1991, Archives of otolaryngology--head & neck surgery.
[600] Nathan Schnaper,et al. Handbook of Psychooncology: Psychological Care of the Patient with Cancer , 1991 .
[601] D. Schultz,et al. The effect of palliative radiation therapy on epidural compression due to metastatic malignant melanoma , 1991, Cancer.
[602] R. Prentice,et al. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[603] N. Cascinelli,et al. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. , 1991, Archives of surgery.
[604] N. Dubin,et al. Survival with regional and distant metastases from cutaneous malignant melanoma. , 1991, Surgery, gynecology & obstetrics.
[605] J. Cooper,et al. Fraction size in external beam radiation therapy in the treatment of melanoma. , 1991, International journal of radiation oncology, biology, physics.
[606] H. Seigler,et al. The role of resection in the management of melanoma metastatic to the adrenal gland. , 1991, Surgery.
[607] M. Avril,et al. [Surgery of pulmonary metastasis from malignant melanoma. Results and criteria of surgical excision]. , 1991, Annales de dermatologie et de venereologie.
[608] C. Grin,et al. Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic-nevus) syndrome. , 1991, The Journal of dermatologic surgery and oncology.
[609] R. Elashoff,et al. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. , 1991, Annals of Surgery.
[610] J. Grob,et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma , 1990, Cancer.
[611] D. Driscoll,et al. Axillary node dissection in malignant melanoma: results and complications. , 1990, Surgery.
[612] L. Anderson,et al. Role of brachytherapy in malignant melanoma: A preliminary report , 1990, Journal of surgical oncology.
[613] R. Schuppli. Die adjuvante Behandlung des malignen Melanoms mit Iscador c. Hg. , 1990 .
[614] A. Derdiarian. Effects of information on recently diagnosed cancer patients' and spouses' satisfaction with care , 1989, Cancer nursing.
[615] J. Sanders,et al. Evaluation of staging workup in malignant melanoma. , 1989, Archives of surgery.
[616] G. Trevisan,et al. [Thymopentin in the treatment of cutaneous melanoma]. , 1989, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.
[617] D. Coit,et al. Extent of lymph node dissection in melanoma of the trunk or lower extremity. , 1989, Archives of surgery.
[618] H. Strander,et al. Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: A randomized phase II study , 1989, Medical oncology and tumor pharmacotherapy.
[619] H. Mameghan,et al. Response of melanoma to heat and radiation therapy —a review of the literature and experience from The Prince of Wales Hospital, Sydney , 1988, The Medical journal of Australia.
[620] L. Solin,et al. Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression. , 1988, International journal of radiation oncology, biology, physics.
[621] F. Jackson,et al. Multimodality Detection of Metastatic Melanoma , 1988, Journal of the Royal Society of Medicine.
[622] J. Fontanesi,et al. Radiotherapy in the management of cutaneous melanoma: effect of time, dose, and fractionation. , 1988, Frontiers of radiation therapy and oncology.
[623] J. Thompson,et al. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. , 1988, Surgery, gynecology & obstetrics.
[624] H. Deicher,et al. Intralesional interferon‐alpha therapy in advanced malignant melanoma , 1988, Cancer.
[625] M. Pilepich,et al. Analysis of dose fractionation in the palliation of metastases from malignant melanoma , 1988, Cancer.
[626] C. Karakousis,et al. Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG , 1987, Journal of surgical oncology.
[627] E. Holly,et al. Number of melanocytic nevi as a major risk factor for malignant melanoma. , 1987, Journal of the American Academy of Dermatology.
[628] B. Emami,et al. Malignant melanoma: analysis of dose fractionation in radiation therapy. , 1987, Radiology.
[629] J. Hanley,et al. Double blind randomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma. , 1987, Clinical and investigative medicine. Medecine clinique et experimentale.
[630] A. Ardizzoni,et al. Stage I-II melanoma: the value of metastatic work-up. , 1987, Oncology.
[631] W. Robinson,et al. Metastatic disease in patients with newly diagnosed malignant melanoma , 1987, Journal of surgical oncology.
[632] J. Overgaard,et al. Hyperthermia as an adjuvant to radiotherapy in the treatment of malignant melanoma. , 1987, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[633] C. Balch,et al. Surgery as Palliative Treatment for Distant Metastases of Melanoma , 1986, Annals of surgery.
[634] J. Overgaard,et al. Some factors of importance in the radiation treatment of malignant melanoma. , 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[635] G. Goerz,et al. [Malignant melanoma: which examinations are useful in staging and follow-up?]. , 1986, Deutsche medizinische Wochenschrift.
[636] M. S. Blois,et al. Frequency and duration of patient follow-up after treatment of a primary malignant melanoma. , 1985, Journal of the American Academy of Dermatology.
[637] D. Osoba,et al. The value of staging and serial follow‐up investigations in patients with completely resected, primary, cutaneous malignant melanoma , 1985, The British journal of surgery.
[638] H. Strander,et al. Adjuvant chemotherapy of malignant melanoma. A pilot study. , 1985, American journal of clinical oncology.
[639] M. N. Epstein,et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. , 1984, Human pathology.
[640] J. Müller,et al. A Prospective Randomized Study of Regional Extremity Perfusion in Patients with Malignant Melanoma , 1984, Annals of surgery.
[641] J. Kirkwood,et al. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[642] A. Harwood. Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna melanoma. , 1983, International journal of radiation oncology, biology, physics.
[643] Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases. , 1983, Canadian Medical Association journal.
[644] J. Armand,et al. [Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone]. , 1982, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.
[645] L. Doss,et al. The radioresponsiveness of melanoma. , 1982, International journal of radiation oncology, biology, physics.
[646] A. Gomes,et al. Thermochemotherapy for melanoma metastases in liver , 1982, Cancer.
[647] N. Cascinelli,et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. , 1982, The New England journal of medicine.
[648] B. Brown,et al. Excision of underlying fascia with a primary malignant melanoma: effect on recurrence and survival rates. , 1982, Surgery.
[649] R. Fisher,et al. Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial. , 1981, The Surgical clinics of North America.
[650] H. Katz. The results of different fractionation schemes in the palliative irradiation of metastatic melanoma. , 1981, International journal of radiation oncology, biology, physics.
[651] S. Moss,et al. DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) surgical adjuvant study COG PROTOCOL 7040 , 1981, Cancer.
[652] A. Dritschilo,et al. Radiation therapy of malignant melanomas: an evaluation of clinically used fractionation schemes. , 1979, Cancer.
[653] J. Chao,et al. Radiotherapy in the management of malignant melanoma. , 1981, International journal of radiation oncology, biology, physics.
[654] R. Sagebiel,et al. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. , 1991, The New England journal of medicine.
[655] D. Morton,et al. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guérin and hyperthermic perfusion. , 1979, Surgery, gynecology & obstetrics.
[656] D. Schoenfeld,et al. Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma , 1979, Cancer.
[657] D. Mathisen,et al. The role of thoracotomy in the management of pulmonary metastases from malignant melanoma. , 1979, The Annals of thoracic surgery.
[658] F. Sim,et al. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma. A randomized, prospective study , 1978, Cancer.
[659] J. Epstein. Photocarcinogenesis: a review. , 1978, National Cancer Institute monograph.
[660] E. Krementz,et al. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065). , 1976, Cancer treatment reports.